Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer

[1]  Huang Jun,et al.  Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype , 2014 .

[2]  Y. Zhang,et al.  Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis , 2013, Oncogene.

[3]  A. Harris,et al.  How cancer metabolism is tuned for proliferation and vulnerable to disruption , 2012, Nature.

[4]  D. Hwang,et al.  Phospholipase signalling networks in cancer , 2012, Nature Reviews Cancer.

[5]  T. Bathen,et al.  Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer , 2012, Proceedings of the National Academy of Sciences.

[6]  E. M. Lindholm,et al.  In vivo MRI and histopathological assessment of tumor microenvironment in luminal‐like and basal‐like breast cancer xenografts , 2012, Journal of magnetic resonance imaging : JMRI.

[7]  P. Pandolfi,et al.  The functions and regulation of the PTEN tumour suppressor , 2012, Nature Reviews Molecular Cell Biology.

[8]  I. Gribbestad,et al.  13C High‐resolution‐magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns , 2011, NMR in biomedicine.

[9]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[10]  Carlos L Arteaga,et al.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer , 2011, Breast Cancer Research.

[11]  M. Leach,et al.  Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents , 2011, Cell cycle.

[12]  R. Blasberg,et al.  Metabolic Imaging: A Link between Lactate Dehydrogenase A, Lactate, and Tumor Phenotype , 2011, Clinical Cancer Research.

[13]  B. Weigelt,et al.  PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.

[14]  J. Kurhanewicz,et al.  Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environment , 2011, NMR in biomedicine.

[15]  I. Gribbestad,et al.  MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer , 2011, NMR in biomedicine.

[16]  M. Pisanu,et al.  MR evaluation of response to targeted treatment in cancer cells , 2011, NMR in biomedicine.

[17]  I. Gribbestad,et al.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy , 2011, Molecular oncology.

[18]  John Kurhanewicz,et al.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.

[19]  S. Moulder.  Does the PI3K pathway play a role in basal breast cancer? , 2010, Clinical breast cancer.

[20]  A. Heerschap,et al.  31P Magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono‐ and diesters at 3 T in the human brain: relation with age and spatial differences , 2010, NMR in biomedicine.

[21]  A. Børresen-Dale,et al.  Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models , 2010, BMC Cancer.

[22]  M. Leach,et al.  Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition , 2010, Oncotarget.

[23]  M. Leach,et al.  The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. , 2010, Cancer research.

[24]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[25]  W. Yung,et al.  Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. , 2010, Neuro-oncology.

[26]  Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. , 2010, Chemical reviews.

[27]  G. Mills,et al.  Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression , 2010, British Journal of Cancer.

[28]  Robert L Sutherland,et al.  PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality , 2010, International journal of cancer.

[29]  A. Lane,et al.  Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling , 2010, Oncogene.

[30]  T. Sørlie,et al.  Molecular profiling and characterization of luminal‐like and basal‐like in vivo breast cancer xenograft models , 2009, Molecular oncology.

[31]  J. Klawitter,et al.  Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells , 2009, British journal of pharmacology.

[32]  Eyal Gottlieb,et al.  Metabolic transformation in cancer. , 2009, Carcinogenesis.

[33]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[34]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[35]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[36]  T. Skotland,et al.  Whole-body section fluorescence imaging--a novel method for tissue distribution studies of fluorescent substances. , 2009, Contrast media & molecular imaging.

[37]  I. Ellis,et al.  Triple‐negative/basal‐like breast cancer: review , 2009, Pathology.

[38]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[39]  Emmanuel Barillot,et al.  Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells , 2008, Breast Cancer Research.

[40]  M.-H. Lee,et al.  Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer , 2008, Cellular and Molecular Life Sciences.

[41]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[42]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[43]  P. Atadja,et al.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. , 2008, Neoplasia.

[44]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[45]  J. Baak,et al.  Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age , 2007, Modern Pathology.

[46]  J. Rosen,et al.  Modelling breast cancer: one size does not fit all , 2007, Nature Reviews Cancer.

[47]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[48]  W. Bornmann,et al.  Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy , 2006, Molecular Cancer Therapeutics.

[49]  T. Bathen,et al.  Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters , 2006, NMR in biomedicine.

[50]  Paul Workman,et al.  Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[51]  G. Gobbel,et al.  Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis , 2005, Laboratory Investigation.

[52]  C. Fenoglio-Preiser,et al.  Stability of Phosphoprotein as a Biological Marker of Tumor Signaling , 2005, Clinical Cancer Research.

[53]  I. Pollack,et al.  Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies , 2005, Laboratory Investigation.

[54]  J. Pollack,et al.  Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins , 2004, Cancer Research.

[55]  D. Megías,et al.  Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression , 2004, Cancer Research.

[56]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[57]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[58]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[59]  J. Lacal,et al.  Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells , 2003, Oncogene.

[60]  G. Semenza,et al.  Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.

[61]  Z. Bhujwalla,et al.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.

[62]  L. del Peso,et al.  Generation of phosphorylcholine as an essential event in the activation of Raf‐1 and MAP‐kinases in growth factors‐induced mitogenic stimulation , 1995, Journal of cellular biochemistry.

[63]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[64]  S. Weinhouse.  On respiratory impairment in cancer cells. , 1956, Science.

[65]  S. Rose.  Transformed cells. , 1949, Scientific American.